Category: Today’s Highlights

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

bluebird bio Suspends LentiGlobin Studies bluebird bio (BLUE) placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD), bb1111, on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

Cassava Sciences Inc Opened Down Today Cassava Sciences, Inc. (SAVA) - a clinical-stage biotech firm focused on the treatment of Alzheimer’s disease, announced that it has entered into a definitive agreement with several healthcare-focused, and other institutional investors, for the purchase of 4,081,633 shares of its common stock at a purchase price of $49.00 per share for . . . This content is for paid subscribers. …

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

Cassava Sciences 2021 Focus and Momentum Cassava Sciences (SAVA) President & CEO, Remi Barbier, informed that the firm has started 2021 with tremendous momentum led by results of a 6-month interim analysis from an open-label study of simufilam, Cassava’s drug candidate for Alzheimer’s disease. Mr. Barbier expressed his belief that the rest of the year may . . . This content is for paid subscribers. …

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results Looking for gene therapy treatments for chronic debilitating life-threatening diseases we fell on news from Spark Therapeutics, a member of the Roche Group (RHHBY); the firm announced preliminary data from part one of the ongoing Phase 1/2 open-label, non-randomized, dose-finding study of the investigational SPK-8016 . . . This content is for paid subscribers. Please click here …

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer’s Patients Following Six Months of Treatment

Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences (SAVA) announced impressive results of an interim analysis from an open-label study of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam improved both patients’ cognition and behavior scores following six months of treatment. There were no safety issues. In a clinical study funded by the National . . . This content is for …

Underlining Exelixis Bright Future

Exelixis Bright Future Exelixis Fourth Quarter and Full Year 2020 Financial Results   Exelixis (EXEL) announced its preliminary unaudited financial results for the Fourth Quarter and Full Year 2020. It also provided financial guidance for the full year 2021 and delivered an update on its business. With regard to Exelixis most important franchise, cabozantinib, the product’s net revenues reached $200 million in the . . . …

For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

Intellia Therapeutics and CRISPR/Cas9 Technology Intellia Therapeutics (NTLA) is a genome editing company, focused on the development of potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment and creating enhanced . . . This content is for …

Inovio: Exciting News Published in The Lancet

Inovio Phase 1 Data of INO-4800 for COVID-19 Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA Vaccine Candidate, INO-4800, to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses. INO-4800 demonstrates favorable safety and tolerability. No serious adverse events reported. Offers best-in-class thermostability, including a five-year projected shelf life at normal refrigeration temperature and no frozen transport or storage requirements. INOVIO …

Compugen: More Highlighted News

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen (CGEN) and AstraZeneca (AZN) entered into . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

Reata Pharmaceuticals: Why its Stock Price is Down Reata Pharmaceuticals (RETA) announced that it has priced a public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional . . . This content is for paid subscribers. …

The US FDA Approved Alnylam’s OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

Alnylam Announces FDA Approval of OXLUMO™ Injection for PH1 Alnylam (ALNY) announced that the US FDA has approved its subcutaneous OXLUMO™ (lumasiran) injection, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Primary Hyperoxaluria Type 1  PH1 is an ultra-rare genetic disease. It is . . . This content is for …

Why Gilead Sciences Product Lenacapavir Deserves the FDA Granted Breakthrough Therapy Designation. See Also: Cellectis and Sanofi

Gilead Sciences News Results from Phase 2/3 CAPELLA trial evaluating Gilead Sciences (GILD) lenacapavir achieved the primary endpoint in heavily treatment-experienced people with multidrug-resistant HIV-1 infection. The study showed that 88% of participants receiving lenacapavir experienced at least a 0.5 log10 reduction in HIV-1 viral load by the end of 14 days of functional monotherapy as . . . This content is for paid subscribers. Please click here …

Inovio to Proceed with Phase 2 Trial of INO-4800 Vaccine Candidate for COVID-19

Inovio Announced FDA Clearance to Proceed with Trial for COVID-19 Vaccine Candidate Inovio (INO) announced the receipt of the U.S. FDA clearance to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. Inovio Planned Phase 2/3 INNOVATE Trial The INNOVATE trial - a . . . This content is for paid subscribers. Please click here to …

A First in Class Antibody for a Difficult to Treat Stomach Cancer and Maybe Others

Five Prime Therapeutics Antibody Plus Chemotherapy for Stomach Cancer Five Prime Therapeutics (FPRX) announced positive topline results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial compared mFOLFOX6 chemotherapy in combination with bemarituzumab (bema, FPA144) - a first-in-class targeted therapy, in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), non-HER2 positive (

What We Expect to Hear at the Regenxbio Conference Call Today

Regenxbio Conference Call Information Regenxbio will host a conference call today, at 4:30 pm est today, November 4, 2020, to discuss its financial results for the quarter, ended September 30, 2020, and recent operational highlights. To access the live call by phone dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 4107819. To access a live or recorded webcast of the call …

Rhythm Pharmaceuticals Achievements and Q3 Financial Results

Rhythm Pharmaceuticals Rhythm Pharmaceuticals (RYTM) reported financial results and provided a business update for the third quarter ended September 30, 2020. The firm develops treatments of rare genetic disorders of obesity. The FDA has accepted the firm's filed New Drug Application (NDA) for it's product, setmelanotide, for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and . . . This content is for paid subscribers. Please click here …